Incorporating historic information to further improve power when conducting Bayesian information borrowing in basket trials.

Biostatistics

MRC Biostatistics Unit, University of Cambridge, East Forvie Building, Robinson Way, Cambridge, Cambridgeshire, CB2 0SR, United Kingdom.

Published: December 2024


Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

In basket trials a single therapeutic treatment is tested on several patient populations simultaneously, each of which forming a basket, where patients across all baskets on the trial share a common genetic aberration. These trials allow testing of treatments on small groups of patients, however, limited basket sample sizes can result in inadequate precision and power of estimates. It is well known that Bayesian information borrowing models such as the exchangeability-nonexchangeability (EXNEX) model can be implemented to tackle such a problem, drawing on information from one basket when making inference in another. An alternative approach to improve power of estimates, is to incorporate any historical or external information available. This paper considers models that amalgamate both forms of information borrowing, allowing borrowing between baskets in the ongoing trial whilst also drawing on response data from historical sources, with the aim to further improve treatment effect estimates. We propose several Bayesian information borrowing approaches that incorporate historical information into the model. These methods are data-driven, updating the degree of borrowing based on the level of homogeneity between information sources. A thorough simulation study is presented to draw comparisons between the proposed approaches, whilst also comparing to the standard EXNEX model in which no historical information is utilized. The models are also applied to a real-life trial example to demonstrate their performance in practice. We show that the incorporation of historic data under the novel approaches can lead to a substantial improvement in precision and power of treatment effect estimates when such data is homogeneous to the responses in the ongoing trial. Under some approaches, this came alongside an inflation in type I error rate in cases of heterogeneity. However, the use of a power prior in the EXNEX model is shown to increase power and precision, whilst maintaining similar error rates to the standard EXNEX model.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12204204PMC
http://dx.doi.org/10.1093/biostatistics/kxaf016DOI Listing

Publication Analysis

Top Keywords

exnex model
16
bayesian borrowing
12
improve power
8
basket trials
8
precision power
8
power estimates
8
incorporate historical
8
ongoing trial
8
treatment estimates
8
standard exnex
8

Similar Publications

In basket trials a single therapeutic treatment is tested on several patient populations simultaneously, each of which forming a basket, where patients across all baskets on the trial share a common genetic aberration. These trials allow testing of treatments on small groups of patients, however, limited basket sample sizes can result in inadequate precision and power of estimates. It is well known that Bayesian information borrowing models such as the exchangeability-nonexchangeability (EXNEX) model can be implemented to tackle such a problem, drawing on information from one basket when making inference in another.

View Article and Find Full Text PDF

Generalized triple outcome decision-making in basket trials.

J Biopharm Stat

January 2025

Global Statistics & Data Science (GSDS), BeiGene, Beijing, China.

Making the go/no-go decision is critical in Phase II (or Ib) clinical trials. The conventional decision-making framework based on a binary hypothesis testing has been gradually replaced by the TODeM (Triple Outcome Decision-Making) which has three zones of outcomes: go, no-go, and consider. The TODeM provides more flexibility in decision-making with considering both of statistical significance and clinical relevance.

View Article and Find Full Text PDF

Recent innovation in trial design to improve study efficiency has led to the development of basket trials in which a single therapeutic treatment is tested on several patient populations, each of which forms a basket. In a common setting, patients across all baskets share a genetic marker and as such, an assumption can be made that all patients may have a homogeneous response to treatments. Bayesian information borrowing procedures utilize this assumption to draw on information regarding the response in one basket when estimating the response rate in others.

View Article and Find Full Text PDF

Bayesian methods for the analysis of early-phase oncology basket trials with information borrowing across cancer types.

Stat Med

November 2020

Department of Biostatistics and Programming Oncology, Sanofi, Cambridge, Massachusetts, USA.

Research in oncology has changed the focus from histological properties of tumors in a specific organ to a specific genomic aberration potentially shared by multiple cancer types. This motivates the basket trial, which assesses the efficacy of treatment simultaneously on multiple cancer types that have a common aberration. Although the assumption of homogeneous treatment effects seems reasonable given the shared aberration, in reality, the treatment effect may vary by cancer type, and potentially only a subgroup of the cancer types respond to the treatment.

View Article and Find Full Text PDF
Article Synopsis
  • Clinical trials using multiple strata are crucial for studying new treatments, especially in small populations and rare diseases, but can present challenges in data inference.
  • Hierarchical modeling methods, like the proposed exchangeability-nonexchangeability (EXNEX) approach, improve statistical analysis by allowing borrowing of information between similar strata, reducing issues from extreme strata.
  • The EXNEX approach shows promising results in case studies, balancing the degree of borrowing and improving estimation and testing accuracy in early-phase trials.
View Article and Find Full Text PDF